









市場行情
/
股票
/
nasdaq-imcr
/

Immunocore Holdings PLC

IMCR

36.130USD

-0.440-1.20%

收盤 12/26, 16:00（美東）報價延遲15分鐘

1.80B總市值

虧損本益比TTM



Immunocore Holdings PLC

36.130

-0.440-1.20%

概覽公司財務分析

概覽

公司

財務

分析

關於 Immunocore Holdings PLC 公司

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.

Immunocore Holdings PLC簡介



公司代碼IMCR

公司名稱Immunocore Holdings PLC

上市日期Feb 05, 2021

CEOJallal (Bahija)

員工數量493

證券類型Depository Receipt

年結日Feb 05

公司地址92 Park Drive Milton Park

城市ABINGDON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United Kingdom

郵編OX14 4RY

電話441235438600

網址https://www.immunocore.com/

公司代碼IMCR

上市日期Feb 05, 2021

CEOJallal (Bahija)

Immunocore Holdings PLC公司高管



名稱

名稱/職務

職務

持股

持股變動

Prof. John Bell

Independent Chairman of the Board

13.45K

Mr. Roy S. Herbst, M.D., Ph.D.

Non-Executive Independent Director

Mr. Clayton Robertson

Head of Investor Relations

Dr. Bahija Jallal, Ph.D.

Chief Executive Officer, Executive Director

Dr. William Pao, M.D., Ph.D.

Non-Executive Independent Director

Mr. Siddharth Kaul

Non-Executive Independent Director

Ms. Kristine Peterson

Non-Executive Independent Director

Prof. Peter Ratcliffe

Non-Executive Independent Director

Dr. David Berman, M.D., Ph.D.

Head of Research and Development

Mr. Travis Coy

Chief Financial Officer and Head of Corporate Development

名稱

名稱/職務

職務

持股

持股變動

Prof. John Bell

Independent Chairman of the Board

13.45K

Mr. Roy S. Herbst, M.D., Ph.D.

Non-Executive Independent Director

Mr. Clayton Robertson

Head of Investor Relations

Dr. Bahija Jallal, Ph.D.

Chief Executive Officer, Executive Director

Dr. William Pao, M.D., Ph.D.

Non-Executive Independent Director

Mr. Siddharth Kaul

Non-Executive Independent Director

收入明細

單位: USD更新時間: 10月6日週一

FY2024

FY2023

FY2023Q3

FY2023Q2

FY2022

FY2022Q3

FY2022Q2

FY2020

FY2019

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

226.69M

73.08%

Europe

73.22M

23.61%

International

10.08M

3.25%

Collaboration revenue

213.00K

0.07%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

T. Rowe Price Investment Management, Inc.

14.19%

RTW Investments L.P.

9.78%

Wellington Management Company, LLP

9.60%

Fidelity Management & Research Company LLC

8.81%

PRIMECAP Management Company

7.54%

其他

50.08%

持股股東

佔比

T. Rowe Price Investment Management, Inc.

14.19%

RTW Investments L.P.

9.78%

Wellington Management Company, LLP

9.60%

Fidelity Management & Research Company LLC

8.81%

PRIMECAP Management Company

7.54%

其他

50.08%

股東類型

持股股東

佔比

Investment Advisor

43.18%

Hedge Fund

28.59%

Investment Advisor/Hedge Fund

24.53%

Venture Capital

1.71%

Research Firm

1.62%

Private Equity

0.77%

Pension Fund

0.56%

Bank and Trust

0.07%

Family Office

0.05%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

300

49.40M

99.22%

-6.80M

2025Q2

293

49.19M

99.31%

-10.02M

2025Q1

304

50.82M

102.67%

-9.36M

2024Q4

304

48.99M

99.30%

-7.33M

2024Q3

299

49.26M

99.94%

-5.38M

2024Q2

298

47.15M

96.58%

+1.62M

2024Q1

283

47.77M

97.93%

+3.51M

2023Q4

262

40.76M

86.07%

-2.70M

2023Q3

246

44.95M

95.97%

-1.86M

2023Q2

236

43.68M

94.12%

-435.38K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

T. Rowe Price Investment Management, Inc.

7.07M

14.03%

+15.84K

+0.22%

Jun 30, 2025

RTW Investments L.P.

4.87M

9.66%

Jun 30, 2025

Wellington Management Company, LLP

5.13M

10.19%

+919.32K

+21.82%

Jul 31, 2025

Fidelity Management & Research Company LLC

4.82M

9.57%

+15.08K

+0.31%

Jun 30, 2025

PRIMECAP Management Company

3.77M

7.49%

+1.09M

+40.80%

Jun 30, 2025

Bellevue Asset Management AG

2.44M

4.85%

+1.22M

+99.86%

Jun 30, 2025

Tang Capital Management, LLC

2.11M

4.18%

+189.90K

+9.91%

Jun 30, 2025

Baker Bros. Advisors LP

2.32M

4.61%

Jun 30, 2025

Deep Track Capital LP

1.80M

3.57%

+388.60K

+27.53%

Jun 30, 2025

BVF Partners L.P.

1.02M

2.03%

+1.02M

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Virtus LifeSci Biotech Products ETF

1.49%

Tema Oncology ETF

1.11%

ALPS Medical Breakthroughs ETF

0.7%

ProShares Ultra Nasdaq Biotechnology

0.19%

SPDR S&P International Small Cap ETF

0.17%

Invesco Nasdaq Biotechnology ETF

0.13%

iShares Intl Small Cap Equity Factor ETF

0.12%

iShares Biotechnology ETF

0.1%

SPDR Portfolio Developed World ex-US ETF

0.01%

Fidelity Nasdaq Composite Index ETF

0.01%

Virtus LifeSci Biotech Products ETF

佔比1.49%

Tema Oncology ETF

佔比1.11%

ALPS Medical Breakthroughs ETF

佔比0.7%

ProShares Ultra Nasdaq Biotechnology

佔比0.19%

SPDR S&P International Small Cap ETF

佔比0.17%

Invesco Nasdaq Biotechnology ETF

佔比0.13%

iShares Intl Small Cap Equity Factor ETF

佔比0.12%

iShares Biotechnology ETF

佔比0.1%

SPDR Portfolio Developed World ex-US ETF

佔比0.01%

Fidelity Nasdaq Composite Index ETF

佔比0.01%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Immunocore Holdings PLC的前五大股東是誰？



Immunocore Holdings PLC的前五大股東如下：
T. Rowe Price Investment Management, Inc.
持有股份：7.07M
佔總股份比例：14.03%。
RTW Investments L.P.
持有股份：4.87M
佔總股份比例：9.66%。
Wellington Management Company, LLP
持有股份：5.13M
佔總股份比例：10.19%。
Fidelity Management & Research Company LLC
持有股份：4.82M
佔總股份比例：9.57%。
PRIMECAP Management Company
持有股份：3.77M
佔總股份比例：7.49%。